T-cell immunotherapy: Looking forward

Jacqueline Corrigan-Curay; Hans Peter Kiem; David Baltimore; Marina O'Reilly; Renier J. Brentjens; Laurence Cooper; Stephen Forman; Stephen Gottschalk; Philip Greenberg; Richard Junghans; Helen Heslop; Michael Jensen; Crystal Mackall; Carl June; Oliver Press; Daniel Powell; Antoni Ribas; Steven Rosenberg; Michel Sadelain; Brian Till; Amy P. Patterson; Robert C. Jambou; Eugene Rosenthal; Linda Gargiulo; Maureen Montgomery; Donald B. Kohn

doi:10.1038/mt.2014.148

T-cell immunotherapy: Looking forward

Jacqueline Corrigan-Curay, Hans Peter Kiem, David Baltimore, Marina O'Reilly, Renier J. Brentjens, Laurence Cooper, Stephen Forman, Stephen Gottschalk, Philip Greenberg, Richard Junghans, Helen Heslop, Michael Jensen, Crystal Mackall, Carl June, Oliver Press, Daniel Powell, Antoni Ribas, Steven Rosenberg, Michel Sadelain, Brian TillAmy P. Patterson, Robert C. Jambou, Eugene Rosenthal, Linda Gargiulo, Maureen Montgomery, Donald B. Kohn

School of Medicine

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. "T Cell Immunotherapy: Optimizing Trial Design," a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach.

Original language	English (US)
Pages (from-to)	1564-1574
Number of pages	11
Journal	Molecular Therapy
Volume	22
Issue number	9
DOIs	https://doi.org/10.1038/mt.2014.148
State	Published - Sep 2014

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

Access to Document

10.1038/mt.2014.148

Cite this

Corrigan-Curay, J., Kiem, H. P., Baltimore, D., O'Reilly, M., Brentjens, R. J., Cooper, L., Forman, S., Gottschalk, S., Greenberg, P., Junghans, R., Heslop, H., Jensen, M., Mackall, C., June, C., Press, O., Powell, D., Ribas, A., Rosenberg, S., Sadelain, M., ... Kohn, D. B. (2014). T-cell immunotherapy: Looking forward. Molecular Therapy, 22(9), 1564-1574. https://doi.org/10.1038/mt.2014.148

Corrigan-Curay, J, Kiem, HP, Baltimore, D, O'Reilly, M, Brentjens, RJ, Cooper, L, Forman, S, Gottschalk, S, Greenberg, P, Junghans, R, Heslop, H, Jensen, M, Mackall, C, June, C, Press, O, Powell, D, Ribas, A, Rosenberg, S, Sadelain, M, Till, B, Patterson, AP, Jambou, RC, Rosenthal, E, Gargiulo, L, Montgomery, M & Kohn, DB 2014, 'T-cell immunotherapy: Looking forward', Molecular Therapy, vol. 22, no. 9, pp. 1564-1574. https://doi.org/10.1038/mt.2014.148

@article{476de195e0ad4d5681cad8061c69cb83,

title = "T-cell immunotherapy: Looking forward",

abstract = "The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. {"}T Cell Immunotherapy: Optimizing Trial Design,{"} a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach.",

author = "Jacqueline Corrigan-Curay and Kiem, {Hans Peter} and David Baltimore and Marina O'Reilly and Brentjens, {Renier J.} and Laurence Cooper and Stephen Forman and Stephen Gottschalk and Philip Greenberg and Richard Junghans and Helen Heslop and Michael Jensen and Crystal Mackall and Carl June and Oliver Press and Daniel Powell and Antoni Ribas and Steven Rosenberg and Michel Sadelain and Brian Till and Patterson, {Amy P.} and Jambou, {Robert C.} and Eugene Rosenthal and Linda Gargiulo and Maureen Montgomery and Kohn, {Donald B.}",

note = "Funding Information: S.G.{\textquoteright}s institution has research collaborations with Celgene Corporation and bluebird bio. He has been funded by the DANA Foundation, the James S. McDonnell Foundation, and Cancer Prevention Research Institute Texas grant RP101335. H.H. and S.F. are supported by grants P01CA094237, P50CA126752, and U54HL08100 from the NIH and a SCOR award from the Leukemia and Lymphoma Society. Funding Information: C.J. has sponsored research support from No-vartis through a grant that supports research in the field of CARs for oncology. He also has intellectual property in the area of adoptive cell therapy that is owned by the University of Pennsylvania and the US government. This has been licensed to Novartis. Both the university and C.J. may receive royalties; this arrangement is managed in accordance with the University of Pennsylvania policies and oversight.",

year = "2014",

month = sep,

doi = "10.1038/mt.2014.148",

language = "English (US)",

volume = "22",

pages = "1564--1574",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - T-cell immunotherapy

T2 - Looking forward

AU - Corrigan-Curay, Jacqueline

AU - Kiem, Hans Peter

AU - Baltimore, David

AU - O'Reilly, Marina

AU - Brentjens, Renier J.

AU - Cooper, Laurence

AU - Forman, Stephen

AU - Gottschalk, Stephen

AU - Greenberg, Philip

AU - Junghans, Richard

AU - Heslop, Helen

AU - Jensen, Michael

AU - Mackall, Crystal

AU - June, Carl

AU - Press, Oliver

AU - Powell, Daniel

AU - Ribas, Antoni

AU - Rosenberg, Steven

AU - Sadelain, Michel

AU - Till, Brian

AU - Patterson, Amy P.

AU - Jambou, Robert C.

AU - Rosenthal, Eugene

AU - Gargiulo, Linda

AU - Montgomery, Maureen

AU - Kohn, Donald B.

N1 - Funding Information: S.G.’s institution has research collaborations with Celgene Corporation and bluebird bio. He has been funded by the DANA Foundation, the James S. McDonnell Foundation, and Cancer Prevention Research Institute Texas grant RP101335. H.H. and S.F. are supported by grants P01CA094237, P50CA126752, and U54HL08100 from the NIH and a SCOR award from the Leukemia and Lymphoma Society. Funding Information: C.J. has sponsored research support from No-vartis through a grant that supports research in the field of CARs for oncology. He also has intellectual property in the area of adoptive cell therapy that is owned by the University of Pennsylvania and the US government. This has been licensed to Novartis. Both the university and C.J. may receive royalties; this arrangement is managed in accordance with the University of Pennsylvania policies and oversight.

PY - 2014/9

Y1 - 2014/9

N2 - The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. "T Cell Immunotherapy: Optimizing Trial Design," a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach.

AB - The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. "T Cell Immunotherapy: Optimizing Trial Design," a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach.

UR - http://www.scopus.com/inward/record.url?scp=84906850813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906850813&partnerID=8YFLogxK

U2 - 10.1038/mt.2014.148

DO - 10.1038/mt.2014.148

M3 - Article

C2 - 25186558

AN - SCOPUS:84906850813

SN - 1525-0016

VL - 22

SP - 1564

EP - 1574

JO - Molecular Therapy

JF - Molecular Therapy

IS - 9

ER -

T-cell immunotherapy: Looking forward

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this